Your only mesothelioma stage news source! Click on each item to read full story.   Research and Markets: Malignant Mesothelioma - Pipeline Review, Q1 2011 read story Research and Markets has announced the addition of Global Markets Direct's new report "Malignant Mesothelioma   Five Weitz & Luxenberg Asbestos Lawyers Accustomed to Court Success Vie for Victories on Different Stage – a Beachside ... read story The Miles for Meso 8k Run, to be held Feb. 12 in Boca Raton, Fla., offers five of Weitz & Luxenberg’s mesothelioma lawyers an opportunity to educate the public about a deadly form of asbestos-linked cancer and to raise money to help find a cure for it. Proceeds from the 8k race and a two-mile ‘Tribute Walk’ will benefit the Mesothelioma Applied Research Foundation, a cancer research affiliate in ...   Asbestos victims get cash boost read story A MULTI-million dollar injection of funding for asbestos victims will make New South Wales a world leader in the treatment of mesothelioma, a cancer specialist says.   This Week in the Journal of Clinical Pathology read story Silke Lassmann and her colleagues at the University Medical Center in Freiburg, Germany, report in the Journal of Clinical Pathology that Aurora-B protein expression is common in serous, FIGO stage III ovarian carcinomas.   Biomarkers - Technologies, Markets and Companies read story NEW YORK, Feb. 1, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Biomarkers - Technologies,markets and companies http://www.reportlinker.com/p0203536/Biomarkers---Technologiesmarkets-and-companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=GenomicsThis ...   Donation controversy focuses attention on Madison County asbestos litigation read story A court date could be waiting for someone who hasn't even filed a suit.   USPTO issues new patent to PBL's RNAi technology read story Plant Bioscience Limited (PBL) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued out US Patent No. 8,097,710 with fundamental claims directed to methods of inducing gene silencing using short RNA molecules, or DNA constructs encoding short RNA molecules, in a wide range of organisms, including in plants and humans.